Show results for
Refine by
Ocular Disease Articles & Analysis
15 news found
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), ...
A summary of UBX1325 Phase 1 study was presented, and a symposium on the role of cellular senescence in ocular disease were both featured this week to more than 10,000 ophthalmologists and other experts in attendance. ...
(NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven by impaired healing. ...
—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions—has unveiled a corporate rebranding, including a name change and a new logo. ...
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, has named Ted Davis as the company’s new president and CEO. ...
Food and Drug Administration (FDA) 510(k) clearance of the TearCare® System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). The indication clears TearCare for the application of localized heat therapy in adult patients with evaporative DED due to MGD, when used in conjunction with manual expression of the meibomian glands. ...
Osmolarity testing enables clinicians to detect visually significant ocular surface disease, and is considered an essential test by the American Society of Cataract and Refractive Surgery. Abnormal osmolarity can adversely impact accuracy of refractive measurements and the TearLab osmolarity test empowers clinicians to accurately diagnose dry eye ...
BySOFIE
Apart from oncology, biologics have been successful in various therapeutic indications as listed in Annexure A. Ocular diseases previously thought untreatable are being treated quite successfully using biologics. We explore some of the treatments that are helping patients suffering from ophthalmic diseases. According to Anthony DeWilde, ...
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue allografts to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, announced today that they had completed a new round of hiring for their two commercial subsidiaries Bio-Tissue and Amniox Medical. ...
Bio-Tissue, Inc., a TissueTech company and pioneer in the clinical application of human birth tissue allografts to promote regenerative healing for ocular surface disease and disorders, announced today that it has entered into a Vendor Agreement with EyePro Group Purchasing Organization (GPO), LLC. As such, GPO members can now take advantage of membership ...
Manassas, VA (June 1, 2021) - Notal Vision, Inc., a privately held ophthalmic home monitoring services provider focused on early disease detection and treatment monitoring is pleased to announce the closing of a Series D financing co-led by Soleus Capital and the company's majority shareholder Ganot Capital. ...
As part of the alliance, the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases. Under this agreement, BlueRock Therapeutics will have the option to exclusively license from both parties three (3) retinal cell therapy programs focused on dry age-related macular degeneration (AMD) and ...
“We are excited to team with BlueRock Therapeutics to discover and develop cell therapies to reverse the progression of ocular diseases and restore vision for patients impacted by these conditions.” “Millions of patients around the world today are suffering from permanent vision loss as a result of incurable ocular ...
The peer-reviewed data from rodent and human disease models showed that ILB® leads to tissue remodelling, reduced fibrosis and functional tissue regeneration – observations indicating the potential of ILB® to alleviate fibrotic diseases. ...
Leo Lens expanded its SAB with four eye care practitioners who are highly experienced in the glaucoma field as the company prepares for its first human clinical trial with its lead asset to treat glaucoma and ocular hypertension. The expanded SAB will provide independent scientific review and guidance to the Company with regards to its R&D activities and product pipeline. ...